<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="682">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01224106</url>
  </required_header>
  <id_info>
    <org_study_id>WN25203</org_study_id>
    <secondary_id>2010-019895-66</secondary_id>
    <nct_id>NCT01224106</nct_id>
  </id_info>
  <brief_title>A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease</brief_title>
  <acronym>Scarlet Road</acronym>
  <official_title>Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, randomized, double-blind, placebo-controlled parallel-group study will&#xD;
      evaluate the effect of gantenerumab (RO4909832) on cognition and functioning and the safety&#xD;
      and pharmacokinetics in participants with prodromal Alzheimer's Disease. Participants will be&#xD;
      randomized to receive subcutaneous (SC) injections of either gantenerumab or placebo.&#xD;
      Participants who consent to be part of the sub study will undergo positron emission&#xD;
      tomography (PET) scanning to assess brain amyloid. The anticipated time on study treatment is&#xD;
      104 weeks in Part 1, with an option for an additional up to 2 years of treatment in Part 2,&#xD;
      followed by an open-label extension (Part 3) until July 2020.&#xD;
&#xD;
      The dosing for Parts 1 and 2 was stopped after a planned futility interim analysis showed a&#xD;
      low probability of meeting the primary outcome measure with the doses studied. The study has&#xD;
      converted to open-label to investigate higher gantenerumab doses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2010</start_date>
  <completion_date type="Actual">September 10, 2020</completion_date>
  <primary_completion_date type="Actual">September 10, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Total Score at Week 104 (Double-Blind Treatment Phase)</measure>
    <time_frame>Baseline, Week 104</time_frame>
    <description>The CDR (Clinical Dementia Rating) is obtained through semi-structured interviews of participants and informants, and cognitive functioning is rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment. The CDR-SOB (Clinical Dementia Rating-Sum of Boxes) is based on summing each of the domain box scores with total scores ranging from 0-18, where lower total scores represent better outcomes and higher total scores represent worse outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) (OLE Phase)</measure>
    <time_frame>Baseline up until a maximum of 5 years</time_frame>
    <description>An Adverse Event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog-11) Scores at Week 104 (Double-Blind Treatment Phase)</measure>
    <time_frame>Baseline, Week 104</time_frame>
    <description>The ADAS-Cog-11 assesses multiple cognitive domains including memory, comprehension, praxis, orientation, and spontaneous speech. Most of these are assessed by tests although some are rated by the clinician on a 5-point scale. The score range for ADAS-Cog-11 is from 0 to 70 with higher scores representing severe dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Dementia at Week 104 (Double-Blind Treatment Phase)</measure>
    <time_frame>Baseline, Week 104</time_frame>
    <description>Time to Onset of Dementia was defined as the time interval between the first treatment date and the date that participant is assessed as having Alzheimer-type dementia by investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Composite Score at Week 104 (Double-Blind Treatment Phase)</measure>
    <time_frame>Baseline, Week 104</time_frame>
    <description>The Cambridge Neuropsychological Test Automated Battery (CANTAB) Â® is a cognitive test battery that incorporates a variety of executive and memory tasks in order to assess neuropsychological function. The end outcome as reported below, is a Z-Composite Score. The score range of the Z-Composite Score is from (-) infinity to (+) infinity with a score of zero representing the population mean, lower (negative) scores representing poorer cognitive outcomes and higher (positive) scores representing better cognitive outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Free and Cued Selective Reminding Test (FCSRT) Score at Week 104 (Double-Blind Treatment Phase)</measure>
    <time_frame>Baseline, Week 104</time_frame>
    <description>FCSRT assesses verbal episodic memory. Performances in free recalls, cued recalls and in a recognition task were analyzed, as the process of encoding is controlled. Participants were asked to remember a list of 16 words. Three tasks of free and cued recalls, as well as 1 recognition task and one delayed recall give the scores. Total recall was obtained by the addition of cued recalls to free recalls. Maximum score is 48 for immediate: 16 words multiplied by (*) 3 corresponding to immediate free recall + immediate cued recall + immediate recognition test. Maximum score is 64 (better score) when delayed recall: 16 words*4. The minimum score is 0 (worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Functional Activities Questionnaire (FAQ) Score at Week 104 (Double-Blind Treatment Phase)</measure>
    <time_frame>Baseline, Week 104</time_frame>
    <description>Participants completed the FAQ for physical function. Overall scores ranged from 0 (independent) to 30 (dependent) where lower scores represented an improvement in physical function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CDR-Global Score at Week 104 (Double-Blind Treatment Phase)</measure>
    <time_frame>Baseline, Week 104</time_frame>
    <description>The CDR-GS represents a semi-structured interview which rates impairment in 6 categories (memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care) on a 5-point scale in which CDR 0 = no dementia and CDR 0.5, 1, 2 or 3 = questionable, mild, moderate or severe dementia respectively. The range in scores for the CDR-GS is from 0 to 3 and a high score on the CDR-GS would indicate a high disease severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Neuropsychiatric Inventory (NPI) Questionnaire Score at Week 104 (Double-Blind Treatment Phase)</measure>
    <time_frame>Baseline, Week 104</time_frame>
    <description>The NPI is a retrospective (to 1 month) caregiver-informant interview assessing frequency and severity of 12 neuropsychiatric symptom domains. The NPI score is based on the sum of the severity ratings (0=absent, 1=mild, 3=severe). The 12 symptom domains include delusions, hallucinations, agitation/aggression, dysphoria/depression, anxiety, euphoria/elation, apathy/indifference, disinhibition, irritability/lability, aberrant motor behaviors, nighttime behavioral disturbances, and appetite/eating abnormalities. The NPI severity score is based on severity ratings (0=absent, 1=mild to 3=severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Cerebrospinal Fluid Biomarkers (Phosphorylated-tau [P-tau], Amyloid Beta 1-42 [Abeta 1-42], Total Tau [T-tau]) at Week 104 (Double-Blind Treatment Phase)</measure>
    <time_frame>Baseline, Week 104</time_frame>
    <description>CSF biomarker phospho-tau (p-tau) is an indicator of neuronal injury and neurodegeneration. An elevation in levels of tau, as well as specific p-tau species, is thought to be a marker for progressive cellular degeneration in AD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Hippocampal Volume at Week 104 (Double-Blind Treatment Phase)</measure>
    <time_frame>Baseline, Week 104</time_frame>
    <description>Change from baseline in hippocampal right volume (HRV) and hippocampal left volume (HLV) were analysed at Week 104 using magnetic resonance imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Cortical Composite Sustained Uptake Volume Ratio (SUVr) in Different Brain Regions at Week 156 (Double-Blind Treatment Phase)</measure>
    <time_frame>Baseline, Week 156</time_frame>
    <description>The different regions of the brain that were analyzed included cerebellum gray, whole cerebellum, composite white matter, subcortical white matter, pons and composite reference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gantenerumab Plasma Concentrations at Different Time Points (Double-Blind Treatment Phase)</measure>
    <time_frame>Pre-Dose: Weeks 8, 20, 44, 68 and 100; Post-Dose: Weeks 1, 53 and 101</time_frame>
    <description>The PK analyses includes tabulation of plasma concentration data and summarisation of plasma concentrations by visits with participants grouped according to treatment received. Descriptive summary statistics for the Arithmetic Mean and Standard Deviation are presented below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Mini Mental State Exam (MMSE) Score at Week 104 (Double-Blind Treatment Phase)</measure>
    <time_frame>Baseline, Week 104</time_frame>
    <description>The MMSE is a brief, practical screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) (Double-Blind Treatment Phase)</measure>
    <time_frame>Baseline up until a maximum of 4.5 years</time_frame>
    <description>An Adverse Event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Drug Antibodies (ADAs) (Double-Blind Treatment Phase)</measure>
    <time_frame>Baseline up until a maximum of 4.5 years</time_frame>
    <description>Participants were considered positive or negative for ADA based on their baseline and post-baseline sample results. The number and percentage of participants with confirmed positive ADA levels were determined for Gantenerumab and Placebo groups. The prevalence of ADA at baseline was calculated as the proportion of participants with confirmed positive ADA levels at baseline relative to the total number of participants with a sample available at baseline. The incidence of treatment-emergent ADAs was determined as the proportion of participants with confirmed post-baseline positive ADAs relative to the total number of participants that had at least one post-baseline sample available for ADA analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog-11) Scores at Week 156 (OLE Phase)</measure>
    <time_frame>Baseline, Week 156</time_frame>
    <description>The ADAS-Cog-11 assesses multiple cognitive domains including memory, comprehension, praxis, orientation, and spontaneous speech. Most of these are assessed by tests although some are rated by the clinician on a 5-point scale. The score range for ADAS-Cog-11 is from 0 to 70 with higher scores representing severe dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Total Score at Week 156 (OLE Phase)</measure>
    <time_frame>Baseline, Week 156</time_frame>
    <description>The CDR (Clinical Dementia Rating) is obtained through semi-structured interviews of participants and informants, and cognitive functioning is rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment. The CDR-SOB (Clinical Dementia Rating-Sum of Boxes) is based on summing each of the domain box scores with total scores ranging from 0-18, where lower total scores represent better outcomes and higher total scores represent worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog-13) Scores at Week 156 (OLE Phase)</measure>
    <time_frame>Baseline, Week 156</time_frame>
    <description>The ADAS-Cog-13 assesses multiple cognitive domains including memory, comprehension, praxis, orientation, and spontaneous speech. The score range for ADAS-Cog-13 is from 0 to 85 with higher scores representing severe dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Dementia at Week 156 (OLE Phase)</measure>
    <time_frame>Baseline, Week 156</time_frame>
    <description>Time to Onset of Dementia was defined as the time interval between the first treatment date and the date that participant is assessed as having Alzheimer-type dementia by investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Free and Cued Selective Reminding Test (FCSRT) Score at Week 156 (OLE Phase)</measure>
    <time_frame>Baseline, Week 156</time_frame>
    <description>FCSRT assesses verbal episodic memory. Performances in free recalls, cued recalls and in a recognition task were analyzed, as the process of encoding is controlled. Participants were asked to remember a list of 16 words. Three tasks of free and cued recalls, as well as 1 recognition task and one delayed recall give the scores. Total recall was obtained by the addition of cued recalls to free recalls. Maximum score is 48 for immediate: 16 words multiplied by (*) 3 corresponding to immediate free recall + immediate cued recall + immediate recognition test. Maximum score is 64 (better score) when delayed recall: 16 words*4. The minimum score is 0 (worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Functional Activities Questionnaire (FAQ) Score at Week 156 (OLE Phase)</measure>
    <time_frame>Baseline, Week 156</time_frame>
    <description>Participants completed the FAQ for physical function. Overall scores ranged from 0 (independent) to 30 (dependent) where lower scores represented an improvement in physical function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CDR-Global Score at Week 156 (OLE Phase)</measure>
    <time_frame>Baseline, Week 156</time_frame>
    <description>The CDR-GS represents a semi-structured interview which rates impairment in 6 categories (memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care) on a 5-point scale in which CDR 0 = no dementia and CDR 0.5, 1, 2 or 3 = questionable, mild, moderate or severe dementia respectively. The range in scores for the CDR-GS is from 0 to 3 and a high score on the CDR-GS would indicate a high disease severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Hippocampal Volume at Week 152 (OLE Phase)</measure>
    <time_frame>Baseline, Week 152</time_frame>
    <description>Change from baseline in hippocampal right volume (HRV) and hippocampal left volume (HLV) were analysed at Week 152 using magnetic resonance imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Cortical Composite Sustained Uptake Volume Ratio (SUVr) in Different Brain Regions at Week 156 (OLE Phase)</measure>
    <time_frame>Baseline, Week 156</time_frame>
    <description>The regions of the brain that were analyzed included cerebellum gray and composite reference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gantenerumab Plasma Concentrations at Different Time Points (OLE Phase)</measure>
    <time_frame>Pre-Dose: Weeks 64, 100, 104, 136, 156 and 208; Post-Dose: Week 101</time_frame>
    <description>The PK analyses includes tabulation of plasma concentration data and summarisation of plasma concentrations by visits with participants grouped according to treatment received. Descriptive summary statistics for the Arithmetic Mean and Standard Deviation are presented below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Mini Mental State Exam (MMSE) Score at Week 156 (OLE Phase)</measure>
    <time_frame>Baseline, Week 156</time_frame>
    <description>The MMSE is a brief, practical screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Drug Antibodies (ADAs) (OLE Phase)</measure>
    <time_frame>Baseline up until a maximum of 5 years</time_frame>
    <description>Participants were considered positive or negative for ADA based on their baseline and post-baseline sample results. The number and percentage of participants with confirmed positive ADA levels were determined. The prevalence of ADA at baseline was calculated as the proportion of participants with confirmed positive ADA levels at baseline relative to the total number of participants with a sample available at baseline. The incidence of treatment-emergent ADAs was determined as the proportion of participants with confirmed post-baseline positive ADAs relative to the total number of participants that had at least one post-baseline sample available for ADA analysis.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">799</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo (Parts 1 and 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with Alzheimer's disease received Placebo by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gantenerumab 105 mg (Parts 1 and 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gantenerumab 225 mg (Parts 1 and 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Parts 1 and 2) switched to Gantenerumab Up to 1200mg (Part 3 Open-Label Extension [OLE])</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with Alzheimer's disease who had received Placebo by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gantenerumab</intervention_name>
    <description>Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.</description>
    <arm_group_label>Gantenerumab 105 mg (Parts 1 and 2)</arm_group_label>
    <arm_group_label>Gantenerumab 225 mg (Parts 1 and 2)</arm_group_label>
    <arm_group_label>Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])</arm_group_label>
    <arm_group_label>Placebo (Parts 1 and 2) switched to Gantenerumab Up to 1200mg (Part 3 Open-Label Extension [OLE])</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants received Placebo SC injection Q4W.</description>
    <arm_group_label>Placebo (Parts 1 and 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult participants, 50-85 years of age&#xD;
&#xD;
          -  Participants with prodromal Alzheimer's disease who are not receiving memantine or&#xD;
             cholinesterase inhibitors&#xD;
&#xD;
          -  Has a study partner who in the investigator's judgement has frequent and sufficient&#xD;
             contact with the participant as to be able to provide accurate information as to the&#xD;
             participant's cognitive and functional abilities, who agrees to provide information at&#xD;
             clinic visits which require partner input for scale completion&#xD;
&#xD;
          -  Has had sufficient education or work experience to exclude mental retardation&#xD;
&#xD;
          -  Study partner has noticed a recent gradual decrease in participant's memory (over the&#xD;
             last 12 months), which the participant may or may not be aware of&#xD;
&#xD;
          -  Screening Mini Mental State Exam (MMSE) score of 24 or above&#xD;
&#xD;
        Additional inclusion criteria for sub study:&#xD;
&#xD;
          -  Able and willing to travel to PET imaging center and complete the planned scanning&#xD;
             sessions&#xD;
&#xD;
          -  Past and planned exposure to ionizing radiation not exceeding safe and permissible&#xD;
             levels&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other prior or current neurologic or medical disorder which may currently or during&#xD;
             the course of the study impair cognition or psychiatric functioning&#xD;
&#xD;
          -  A history of stroke&#xD;
&#xD;
          -  A documented history of transient ischemic attack within the last 12 months&#xD;
&#xD;
          -  History of schizophrenia, schizoaffective or bipolar disorder&#xD;
&#xD;
          -  Currently meets criteria for major depression&#xD;
&#xD;
          -  Within the last 2 years, unstable or clinical significant cardiovascular disease&#xD;
             (myocardial infarction, angina pectoris)&#xD;
&#xD;
        Additional exclusion criteria for sub study:&#xD;
&#xD;
          -  Inclusion in a research and/or medical protocol involving PET ligands or other&#xD;
             radioactive agents within 12 months&#xD;
&#xD;
          -  Present or planned participation in a research and/or medical protocol involving PET&#xD;
             ligands or radioactive agents other than study WN25203&#xD;
&#xD;
          -  Have planned or are planning to have exposure to ionizing radiation that in&#xD;
             combination with the planned administration with study amyloid PET ligand would result&#xD;
             in a cumulative exposure that exceeds local recommended exposure limits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner Alzheimer's Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University ADRU</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research, Inc.</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelerated Enrollment Solutions</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskamp Institute, Inc.</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Center for Memory</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Michigan University Homer Stryker M.D. School of Medicine Center for Clinical Research</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Research Center</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princeton Medical Institute</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nathan Kline Institute</name>
      <address>
        <city>Orangeburg</city>
        <state>New York</state>
        <zip>10962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center; Monroe Community Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14627</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alzheimer's Memory Center</name>
      <address>
        <city>Matthews</city>
        <state>North Carolina</state>
        <zip>28105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University, Layton Aging and Alzheimer's Disease Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeastern Pennsylvania Memory</name>
      <address>
        <city>Plains</city>
        <state>Pennsylvania</state>
        <zip>18705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Mood &amp; Memory Research Institute</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senior Adults Specialty Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Neurology PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Research Associates, Inc.</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IME - Instituto MÃ©dico Especializado; Ensayos ClÃ­nicos</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1405BCH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ALPI-Inst. de Rehabilitacion Marcelo Fitte</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425BWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEMIC</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1431FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mulieris</name>
      <address>
        <city>Caba</city>
        <zip>C1022AAO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto De NeurologÃ­a Cognitiva - INECO</name>
      <address>
        <city>Caba</city>
        <zip>C1126AAB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FLENI</name>
      <address>
        <city>Caba</city>
        <zip>C1428AQK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Kremer</name>
      <address>
        <city>CÃ³rdoba</city>
        <zip>X5004AOA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CENPIA; NeurologÃ­a - PsicologÃ­a</name>
      <address>
        <city>La Plata</city>
        <zip>B1902AJU</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hornsby Ku-ring-gai Hospital; Division of Rehabilitation &amp; Aged Care</name>
      <address>
        <city>Hornsby</city>
        <state>New South Wales</state>
        <zip>2077</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital, Academic Department for Old Age Psychiatry</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital; Memory Trials Centre</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital; Neurology</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre</name>
      <address>
        <city>Heidelberg West</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australian Alzheimer's Research Foundation</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas - UFPR; Ciencias da Saude</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas - UFRGS</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mae de Deus</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90470-340</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas - FMUSP; Psiquiatria</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Sao Paulo - UNIFESPX; Neurologia</name>
      <address>
        <city>SÃ£o Paulo</city>
        <state>SP</state>
        <zip>04024-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>True North Clinical Research</name>
      <address>
        <city>New Minas</city>
        <state>Nova Scotia</state>
        <zip>B4N 3R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawartha Centre - Redefining Healthy Aging</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9H 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Memory Program</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Memory and Aging</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroSearch Developpements inc</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University; Sir Mortimer B Davis Jewish General Hospital; Neurological and Psychiatric</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHAUQ - HÃ´pital Enfant-JÃ©sus</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biomedica Research Group</name>
      <address>
        <city>Santiago</city>
        <zip>7500710</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Especialidades Medicas LYS</name>
      <address>
        <city>Santiago</city>
        <zip>7560356</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. AnneÂ´s University Hospital; Clinical Trials Department</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vestra Clinics s.r.o.</name>
      <address>
        <city>Rychnov nad Kneznou</city>
        <zip>516 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital, Neurologisk Afdeling F, Demensklinikken</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Hukommelsesklinikken</name>
      <address>
        <city>Koebenhavn Oe</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRST Oy</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne; Neurologie</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pellegrin; Cmrr Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pierre Wertheimer; Laboratoire De Neuro Psychologie</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU De Caen; Service De Neurologie Dejerine</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital B Roger Salengro; Cmrr Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Pitie Salpetriere; Cmrr Ile De France Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen Hopital; Service de Neurologie</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hop Guillaume Et Rene Laennec; Cmrr St Herblain</name>
      <address>
        <city>St Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Hautepierre; Centre dInvestigation Clinique</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de La Grave</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Berlin; Klin fur Psychi &amp; Psycho Charite</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Bonn; Medizinische Klinik und Poliklinik I; Allgemeine Innere Medizin</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Joh.Wolfg.Goethe-UNI Zentrum d. Psychiatrie Klinik f. Psychiatrie Psychosomatik</name>
      <address>
        <city>Frankfurt</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PANAKEIA - Arzneimittelforschung Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralinstitut fÃ¼r Seelische Gesundheit Abt.Gerontopsychiatrie</name>
      <address>
        <city>Mannheim</city>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmakologisches Studienzentrum</name>
      <address>
        <city>Mittweida</city>
        <zip>09648</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Praxis Dr. Andrej Pauls</name>
      <address>
        <city>MÃ¼nchen</city>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU MÃ¼nchen; Klinik fÃ¼r Psychiatrie und Psychotherapie</name>
      <address>
        <city>MÃ¼nchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr Klaus Steinwachs Neurology &amp; Psychiatry</name>
      <address>
        <city>NÃ¼rnberg</city>
        <zip>90402</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Rostock Zentrum fÃ¼r Nervenheilkunde</name>
      <address>
        <city>Rostock</city>
        <zip>18147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Ulm; Klinik fÃ¼r Neurologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuovo Ospedale Civile S. Agostino-Estense; Clinica Neurologica - Dipartimento di Neuroscienze</name>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita' Di Parma Istituto Neurologia</name>
      <address>
        <city>Parma</city>
        <state>Emilia-Romagna</state>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Spedali Civili; Scienze Neurologiche</name>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS &quot;Centro S. Giovanni di Dio&quot; Fatebenefratelli -UO Alzheimer</name>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Multimedica Santa Maria; Unita' Di Neurologia</name>
      <address>
        <city>Castellanza</city>
        <state>Lombardia</state>
        <zip>21053</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione San Raffaele Del Monte Tabor; Dipartimento Di Neurologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi Di Ancona</name>
      <address>
        <city>Torrette - Ancona</city>
        <state>Marche</state>
        <zip>60100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uni Di Firenze Dip. Scienze Neurol Psic Sod Neurologia 1</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital; Neurology Department</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center.</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mexico Americano</name>
      <address>
        <city>Guadalajara</city>
        <state>Mexico CITY (federal District)</state>
        <zip>44610</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario; Dr. Jose E. Gonzalez</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LEON</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Angeles de CuliacÃ¡n, Neurociencias Estudios ClÃ­nicos SC</name>
      <address>
        <city>Culiacan</city>
        <zip>80020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigacion en Enfermedades Cronico-Degenerativa; Reumatologia</name>
      <address>
        <city>Guadalajara</city>
        <zip>44620</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Estimulacion Magnetica Trnscraneal de Mexico SC.</name>
      <address>
        <city>Mexico City</city>
        <zip>11000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico San Francisco; Geriatrics</name>
      <address>
        <city>Monterrey</city>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Saltillo</name>
      <address>
        <city>Saltillo</city>
        <zip>25000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis; Polikliniek Geriatrie</name>
      <address>
        <city>'S Hertogenbosch</city>
        <zip>5223 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Research Center B.V</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 GN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Podlaskie Centrum Psychogeriatrii</name>
      <address>
        <city>BiaÅystok</city>
        <zip>15-756</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PALLMED Sp. z o.o. prowadzÄca NZOZ DOM SUE RYDER</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEURO - KARD OÅrodek BadaÅ Klinicznych</name>
      <address>
        <city>PoznaÅ</city>
        <zip>61-853</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Przychodnia Specjalistyczna PROSEN</name>
      <address>
        <city>Warszawa</city>
        <zip>01-231</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>mMED Maciej Czarnecki</name>
      <address>
        <city>Warszawa</city>
        <zip>01-684</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Prof. Dr. Fernando Fonseca; Servico de Neurologia</name>
      <address>
        <city>Amadora</city>
        <zip>2720-276</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria; Servico de Neurologia</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Clinical Psychoneurological War Veteran Hospital</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State autonomous institution of healthcare Inter-regional clinical and diagnostic center</name>
      <address>
        <city>Kazan</city>
        <zip>420101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Institution of Healthcare City Geriatric Medico-Social Center</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital # 2 n.a. V.I. Razumovsky</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Medical Military Academy n.a. S.M.Kirov; Neurology Department</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FundaciÃ³ ACE</name>
      <address>
        <city>BArcelon</city>
        <state>Barcelona</state>
        <zip>08034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua De Terrasa; Servicio de Neurologia</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces; Servicio de Neurologia</name>
      <address>
        <city>Barakaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar; Servicio de Neurologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial; Servicio de Neurologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal; Servicio de Neurologia</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre; Servicio de Neurologia</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz; Servicio de Neurologia</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset; Servicio de Neurologia</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SkÃ¥nes Universitetssjukhus MalmÃ¶, Minneskliniken</name>
      <address>
        <city>MalmÃ¶</city>
        <zip>211 46</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Felix Platter-Spital Medizin Geriatrie</name>
      <address>
        <city>Basel</city>
        <zip>4002</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUG; DÃ©partement de santÃ© mentale et de psychiatrie UnitÃ© de psychiatrie gÃ©riatrique</name>
      <address>
        <city>ChÃªne-Bourg</city>
        <zip>1225</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akdeniz University School of Medicine, Neurology Department</name>
      <address>
        <city>Antalya</city>
        <zip>07058</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University Istanbul School of Medicine; Neurology</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ondokuz Mayis University School of Medicine; Neurology</name>
      <address>
        <city>Samsun</city>
        <zip>55239</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Llandough Hospital; Llandough Hospital Memory Team 3rd Floor Academic Building</name>
      <address>
        <city>Cardiff</city>
        <zip>CF64 2XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Margaret's Hospital</name>
      <address>
        <city>Epping</city>
        <zip>CM16 6TN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glasgow Memory Clinic</name>
      <address>
        <city>Glasgow</city>
        <zip>G20 0XA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital; Dept of Neurosciences</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Campus for Ageing &amp; Vitality; Clincal Ageing Research Unit</name>
      <address>
        <city>Newcastle</city>
        <zip>NE4 5PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorgreen Hospital; Memory Assessment &amp; Rsch Ctr</name>
      <address>
        <city>Southampton</city>
        <zip>SO30 3JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria Centre; Kingshill Research Centre</name>
      <address>
        <city>Swindon</city>
        <zip>SN3 6BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollins Park Hospital</name>
      <address>
        <city>Warrington</city>
        <zip>WA2 8WA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Israel</country>
  </removed_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>October 14, 2010</study_first_submitted>
  <study_first_submitted_qc>October 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2010</study_first_posted>
  <results_first_submitted>September 8, 2021</results_first_submitted>
  <results_first_submitted_qc>December 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">December 13, 2021</results_first_posted>
  <last_update_submitted>December 10, 2021</last_update_submitted>
  <last_update_submitted_qc>December 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT01224106/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT01224106/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 128 centers in 24 countries.</recruitment_details>
      <pre_assignment_details>A total of 799 participants were randomised in this study. Of these, a total of 797 participants were enrolled and received at least one dose of any study drug and represented the Safety population during the Double-Blind Treatment Phase (Parts 1 and 2 of the study). From the Double-Blind Treatment Phase, a total of 154 participants (at 53 sites) were enrolled into Open-Label Extension (OLE) Phase (Part 3 of the study).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Parts 1 and 2)</title>
          <description>Participants with Alzheimer's disease received Placebo by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
        </group>
        <group group_id="P2">
          <title>Gantenerumab 105 mg (Parts 1 and 2)</title>
          <description>Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
        </group>
        <group group_id="P3">
          <title>Gantenerumab 225 mg (Parts 1 and 2)</title>
          <description>Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
        </group>
        <group group_id="P4">
          <title>Placebo (Parts 1 and 2) Switched to Gantenerumab Up to 1200mg (Part 3 Open-Label Extension [OLE])</title>
          <description>Participants with Alzheimer's disease who had received Placebo by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
        </group>
        <group group_id="P5">
          <title>Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])</title>
          <description>Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="266"/>
                <participants group_id="P2" count="271"/>
                <participants group_id="P3" count="260"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="185"/>
                <participants group_id="P3" count="180"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="86"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant/legal guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parts 1 and 2 Termination by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Extension (OLE) Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 797 participants were enrolled into the Double-Blind Treatment phase of this study and the entire study. A subset (154) of these participants moved into the OLE phase of this study.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo (Parts 1 and 2)</title>
          <description>Participants with Alzheimer's disease received Placebo by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
        </group>
        <group group_id="B2">
          <title>Gantenerumab 105 mg (Parts 1 and 2)</title>
          <description>Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
        </group>
        <group group_id="B3">
          <title>Gantenerumab 225 mg (Parts 1 and 2)</title>
          <description>Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
        </group>
        <group group_id="B4">
          <title>Placebo (Parts 1 and 2) Switched to Gantenerumab Up to 1200mg (Part 3 Open-Label Extension [OLE])</title>
          <description>Participants with Alzheimer's disease who had received Placebo by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
        </group>
        <group group_id="B5">
          <title>Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])</title>
          <description>Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="266"/>
            <count group_id="B2" value="271"/>
            <count group_id="B3" value="260"/>
            <count group_id="B4" value="49"/>
            <count group_id="B5" value="105"/>
            <count group_id="B6" value="951"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Parts 1 and 2 of the study.</description>
          <population>Participants in the Double-Blind Treatment Phase of this study.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="266"/>
                    <count group_id="B2" value="271"/>
                    <count group_id="B3" value="260"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="797"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.5" spread="7.5"/>
                    <measurement group_id="B2" value="70.3" spread="7.0"/>
                    <measurement group_id="B3" value="71.3" spread="7.1"/>
                    <measurement group_id="B6" value="70.4" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Part 3 of the study.</description>
          <population>Participants in the OLE Phase of this study.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="105"/>
                    <count group_id="B6" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="75.5" spread="5.8"/>
                    <measurement group_id="B5" value="73.7" spread="7.3"/>
                    <measurement group_id="B6" value="74.3" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Parts 1 and 2 of the study.</description>
          <population>Participants in the Double-Blind Treatment Phase of this study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="266"/>
                    <count group_id="B2" value="271"/>
                    <count group_id="B3" value="260"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="797"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="152"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="453"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Part 3 of the study.</description>
          <population>Participants in the OLE Phase of this study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="105"/>
                    <count group_id="B6" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="64"/>
                    <measurement group_id="B6" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Parts 1 and 2 of the study.</description>
          <population>Participants in the Double-Blind Treatment Phase of this study.</population>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non-Hispanic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="266"/>
                    <count group_id="B2" value="271"/>
                    <count group_id="B3" value="260"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="797"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                    <measurement group_id="B2" value="221"/>
                    <measurement group_id="B3" value="210"/>
                    <measurement group_id="B6" value="648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="266"/>
                    <count group_id="B2" value="271"/>
                    <count group_id="B3" value="260"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="797"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B6" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska native</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="266"/>
                    <count group_id="B2" value="271"/>
                    <count group_id="B3" value="260"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="797"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="266"/>
                    <count group_id="B2" value="271"/>
                    <count group_id="B3" value="260"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="797"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="266"/>
                    <count group_id="B2" value="271"/>
                    <count group_id="B3" value="260"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="797"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="266"/>
                    <count group_id="B2" value="271"/>
                    <count group_id="B3" value="260"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="797"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="239"/>
                    <measurement group_id="B2" value="252"/>
                    <measurement group_id="B3" value="239"/>
                    <measurement group_id="B6" value="730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Available</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="266"/>
                    <count group_id="B2" value="271"/>
                    <count group_id="B3" value="260"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="797"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B6" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Part 3 of the study.</description>
          <population>Participants in the OLE Phase of this study.</population>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non-Hispanic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="105"/>
                    <count group_id="B6" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="88"/>
                    <measurement group_id="B6" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="105"/>
                    <count group_id="B6" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska native</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="105"/>
                    <count group_id="B6" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="105"/>
                    <count group_id="B6" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="105"/>
                    <count group_id="B6" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="101"/>
                    <measurement group_id="B6" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="49"/>
                    <count group_id="B5" value="105"/>
                    <count group_id="B6" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Total Score at Week 104 (Double-Blind Treatment Phase)</title>
        <description>The CDR (Clinical Dementia Rating) is obtained through semi-structured interviews of participants and informants, and cognitive functioning is rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment. The CDR-SOB (Clinical Dementia Rating-Sum of Boxes) is based on summing each of the domain box scores with total scores ranging from 0-18, where lower total scores represent better outcomes and higher total scores represent worse outcomes.</description>
        <time_frame>Baseline, Week 104</time_frame>
        <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Placebo by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab 105 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Total Score at Week 104 (Double-Blind Treatment Phase)</title>
          <description>The CDR (Clinical Dementia Rating) is obtained through semi-structured interviews of participants and informants, and cognitive functioning is rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment. The CDR-SOB (Clinical Dementia Rating-Sum of Boxes) is based on summing each of the domain box scores with total scores ranging from 0-18, where lower total scores represent better outcomes and higher total scores represent worse outcomes.</description>
          <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. Data presented below is only for participants included in the actual analysis.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="1.68"/>
                    <measurement group_id="O2" value="1.41" spread="2.02"/>
                    <measurement group_id="O3" value="1.47" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6744</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Effect Size</param_type>
            <param_value>-0.044</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.248</ci_lower_limit>
            <ci_upper_limit>0.161</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4494</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Effect Size</param_type>
            <param_value>-0.085</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.304</ci_lower_limit>
            <ci_upper_limit>0.135</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) (OLE Phase)</title>
        <description>An Adverse Event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
        <time_frame>Baseline up until a maximum of 5 years</time_frame>
        <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2) Switched to Gantenerumab Up to 1200mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Placebo by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) (OLE Phase)</title>
          <description>An Adverse Event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
          <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog-11) Scores at Week 104 (Double-Blind Treatment Phase)</title>
        <description>The ADAS-Cog-11 assesses multiple cognitive domains including memory, comprehension, praxis, orientation, and spontaneous speech. Most of these are assessed by tests although some are rated by the clinician on a 5-point scale. The score range for ADAS-Cog-11 is from 0 to 70 with higher scores representing severe dysfunction.</description>
        <time_frame>Baseline, Week 104</time_frame>
        <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Placebo by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab 105 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog-11) Scores at Week 104 (Double-Blind Treatment Phase)</title>
          <description>The ADAS-Cog-11 assesses multiple cognitive domains including memory, comprehension, praxis, orientation, and spontaneous speech. Most of these are assessed by tests although some are rated by the clinician on a 5-point scale. The score range for ADAS-Cog-11 is from 0 to 70 with higher scores representing severe dysfunction.</description>
          <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. Data presented below is only for participants included in the actual analysis.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68" spread="6.64"/>
                    <measurement group_id="O2" value="3.52" spread="6.28"/>
                    <measurement group_id="O3" value="3.97" spread="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7458</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Effect Size</param_type>
            <param_value>0.035</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.179</ci_lower_limit>
            <ci_upper_limit>0.250</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.723</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Effect Size</param_type>
            <param_value>0.042</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.191</ci_lower_limit>
            <ci_upper_limit>0.275</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Dementia at Week 104 (Double-Blind Treatment Phase)</title>
        <description>Time to Onset of Dementia was defined as the time interval between the first treatment date and the date that participant is assessed as having Alzheimer-type dementia by investigators.</description>
        <time_frame>Baseline, Week 104</time_frame>
        <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Placebo by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab 105 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Dementia at Week 104 (Double-Blind Treatment Phase)</title>
          <description>Time to Onset of Dementia was defined as the time interval between the first treatment date and the date that participant is assessed as having Alzheimer-type dementia by investigators.</description>
          <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.64" lower_limit="56.63" upper_limit="69.82"/>
                    <measurement group_id="O2" value="62.98" lower_limit="56.00" upper_limit="69.16"/>
                    <measurement group_id="O3" value="70.64" lower_limit="63.34" upper_limit="76.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Composite Score at Week 104 (Double-Blind Treatment Phase)</title>
        <description>The Cambridge Neuropsychological Test Automated Battery (CANTAB) Â® is a cognitive test battery that incorporates a variety of executive and memory tasks in order to assess neuropsychological function. The end outcome as reported below, is a Z-Composite Score. The score range of the Z-Composite Score is from (-) infinity to (+) infinity with a score of zero representing the population mean, lower (negative) scores representing poorer cognitive outcomes and higher (positive) scores representing better cognitive outcomes.</description>
        <time_frame>Baseline, Week 104</time_frame>
        <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. The Placebo Match Gantenerumab 225mg (Parts 1 and 2) arm consisted of participants with the ApoE 2e4 mutation who were excluded from the Gantenerumab 225 mg (Parts 1 and 2) arm. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Placebo by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab 105 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Match Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received matching Placebo to Gantenerumab 225 mg by SC injection q4w for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Composite Score at Week 104 (Double-Blind Treatment Phase)</title>
          <description>The Cambridge Neuropsychological Test Automated Battery (CANTAB) Â® is a cognitive test battery that incorporates a variety of executive and memory tasks in order to assess neuropsychological function. The end outcome as reported below, is a Z-Composite Score. The score range of the Z-Composite Score is from (-) infinity to (+) infinity with a score of zero representing the population mean, lower (negative) scores representing poorer cognitive outcomes and higher (positive) scores representing better cognitive outcomes.</description>
          <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. The Placebo Match Gantenerumab 225mg (Parts 1 and 2) arm consisted of participants with the ApoE 2e4 mutation who were excluded from the Gantenerumab 225 mg (Parts 1 and 2) arm. Data presented below is only for participants included in the actual analysis.</population>
          <units>Z-Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.72" spread="2.99"/>
                    <measurement group_id="O2" value="-1.37" spread="2.74"/>
                    <measurement group_id="O3" value="-1.4" spread="3.11"/>
                    <measurement group_id="O4" value="-1.93" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Free and Cued Selective Reminding Test (FCSRT) Score at Week 104 (Double-Blind Treatment Phase)</title>
        <description>FCSRT assesses verbal episodic memory. Performances in free recalls, cued recalls and in a recognition task were analyzed, as the process of encoding is controlled. Participants were asked to remember a list of 16 words. Three tasks of free and cued recalls, as well as 1 recognition task and one delayed recall give the scores. Total recall was obtained by the addition of cued recalls to free recalls. Maximum score is 48 for immediate: 16 words multiplied by (*) 3 corresponding to immediate free recall + immediate cued recall + immediate recognition test. Maximum score is 64 (better score) when delayed recall: 16 words*4. The minimum score is 0 (worse).</description>
        <time_frame>Baseline, Week 104</time_frame>
        <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. The Placebo Match Gantenerumab 225mg (Parts 1 and 2) arm consisted of participants with the ApoE 2e4 mutation who were excluded from the Gantenerumab 225 mg (Parts 1 and 2) arm. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Placebo by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab 105 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Match Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received matching Placebo to Gantenerumab 225 mg by SC injection q4w for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Free and Cued Selective Reminding Test (FCSRT) Score at Week 104 (Double-Blind Treatment Phase)</title>
          <description>FCSRT assesses verbal episodic memory. Performances in free recalls, cued recalls and in a recognition task were analyzed, as the process of encoding is controlled. Participants were asked to remember a list of 16 words. Three tasks of free and cued recalls, as well as 1 recognition task and one delayed recall give the scores. Total recall was obtained by the addition of cued recalls to free recalls. Maximum score is 48 for immediate: 16 words multiplied by (*) 3 corresponding to immediate free recall + immediate cued recall + immediate recognition test. Maximum score is 64 (better score) when delayed recall: 16 words*4. The minimum score is 0 (worse).</description>
          <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. The Placebo Match Gantenerumab 225mg (Parts 1 and 2) arm consisted of participants with the ApoE 2e4 mutation who were excluded from the Gantenerumab 225 mg (Parts 1 and 2) arm. Data presented below is only for participants included in the actual analysis.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="97"/>
                <count group_id="O4" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.05" spread="8.73"/>
                    <measurement group_id="O2" value="-4.11" spread="8.57"/>
                    <measurement group_id="O3" value="-6.42" spread="8.45"/>
                    <measurement group_id="O4" value="-4.05" spread="8.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Functional Activities Questionnaire (FAQ) Score at Week 104 (Double-Blind Treatment Phase)</title>
        <description>Participants completed the FAQ for physical function. Overall scores ranged from 0 (independent) to 30 (dependent) where lower scores represented an improvement in physical function.</description>
        <time_frame>Baseline, Week 104</time_frame>
        <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. The Placebo Match Gantenerumab 225mg (Parts 1 and 2) arm consisted of participants with the ApoE 2e4 mutation who were excluded from the Gantenerumab 225 mg (Parts 1 and 2) arm. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Placebo SC injection (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab 105 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Match Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received matching Placebo to Gantenerumab 225 mg by SC injection q4w for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Functional Activities Questionnaire (FAQ) Score at Week 104 (Double-Blind Treatment Phase)</title>
          <description>Participants completed the FAQ for physical function. Overall scores ranged from 0 (independent) to 30 (dependent) where lower scores represented an improvement in physical function.</description>
          <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. The Placebo Match Gantenerumab 225mg (Parts 1 and 2) arm consisted of participants with the ApoE 2e4 mutation who were excluded from the Gantenerumab 225 mg (Parts 1 and 2) arm. Data presented below is only for participants included in the actual analysis.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59" spread="4.93"/>
                    <measurement group_id="O2" value="4.89" spread="6.2"/>
                    <measurement group_id="O3" value="4.03" spread="5.75"/>
                    <measurement group_id="O4" value="3.6" spread="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0825</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Effect Size</param_type>
            <param_value>-0.191</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.407</ci_lower_limit>
            <ci_upper_limit>0.025</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7171</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Effect Size</param_type>
            <param_value>0.043</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.276</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CDR-Global Score at Week 104 (Double-Blind Treatment Phase)</title>
        <description>The CDR-GS represents a semi-structured interview which rates impairment in 6 categories (memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care) on a 5-point scale in which CDR 0 = no dementia and CDR 0.5, 1, 2 or 3 = questionable, mild, moderate or severe dementia respectively. The range in scores for the CDR-GS is from 0 to 3 and a high score on the CDR-GS would indicate a high disease severity.</description>
        <time_frame>Baseline, Week 104</time_frame>
        <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. The Placebo Match Gantenerumab 225mg (Parts 1 and 2) arm consisted of participants with the ApoE 2e4 mutation who were excluded from the Gantenerumab 225 mg (Parts 1 and 2) arm. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Placebo SC injection (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab 105 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Match Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received matching Placebo to Gantenerumab 225 mg by SC injection q4w for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CDR-Global Score at Week 104 (Double-Blind Treatment Phase)</title>
          <description>The CDR-GS represents a semi-structured interview which rates impairment in 6 categories (memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care) on a 5-point scale in which CDR 0 = no dementia and CDR 0.5, 1, 2 or 3 = questionable, mild, moderate or severe dementia respectively. The range in scores for the CDR-GS is from 0 to 3 and a high score on the CDR-GS would indicate a high disease severity.</description>
          <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. The Placebo Match Gantenerumab 225mg (Parts 1 and 2) arm consisted of participants with the ApoE 2e4 mutation who were excluded from the Gantenerumab 225 mg (Parts 1 and 2) arm. Data presented below is only for participants included in the actual analysis.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.29"/>
                    <measurement group_id="O2" value="0.18" spread="0.36"/>
                    <measurement group_id="O3" value="0.14" spread="0.33"/>
                    <measurement group_id="O4" value="0.1" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Neuropsychiatric Inventory (NPI) Questionnaire Score at Week 104 (Double-Blind Treatment Phase)</title>
        <description>The NPI is a retrospective (to 1 month) caregiver-informant interview assessing frequency and severity of 12 neuropsychiatric symptom domains. The NPI score is based on the sum of the severity ratings (0=absent, 1=mild, 3=severe). The 12 symptom domains include delusions, hallucinations, agitation/aggression, dysphoria/depression, anxiety, euphoria/elation, apathy/indifference, disinhibition, irritability/lability, aberrant motor behaviors, nighttime behavioral disturbances, and appetite/eating abnormalities. The NPI severity score is based on severity ratings (0=absent, 1=mild to 3=severe).</description>
        <time_frame>Baseline, Week 104</time_frame>
        <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. The Placebo Match Gantenerumab 225mg (Parts 1 and 2) arm consisted of participants with the ApoE 2e4 mutation who were excluded from the Gantenerumab 225 mg (Parts 1 and 2) arm. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Placebo SC injection (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab 105 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Match Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received matching Placebo to Gantenerumab 225 mg by SC injection q4w for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Neuropsychiatric Inventory (NPI) Questionnaire Score at Week 104 (Double-Blind Treatment Phase)</title>
          <description>The NPI is a retrospective (to 1 month) caregiver-informant interview assessing frequency and severity of 12 neuropsychiatric symptom domains. The NPI score is based on the sum of the severity ratings (0=absent, 1=mild, 3=severe). The 12 symptom domains include delusions, hallucinations, agitation/aggression, dysphoria/depression, anxiety, euphoria/elation, apathy/indifference, disinhibition, irritability/lability, aberrant motor behaviors, nighttime behavioral disturbances, and appetite/eating abnormalities. The NPI severity score is based on severity ratings (0=absent, 1=mild to 3=severe).</description>
          <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. The Placebo Match Gantenerumab 225mg (Parts 1 and 2) arm consisted of participants with the ApoE 2e4 mutation who were excluded from the Gantenerumab 225 mg (Parts 1 and 2) arm. Data presented below is only for participants included in the actual analysis.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="3.22"/>
                    <measurement group_id="O2" value="0.39" spread="2.57"/>
                    <measurement group_id="O3" value="0.34" spread="2.84"/>
                    <measurement group_id="O4" value="0.72" spread="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Cerebrospinal Fluid Biomarkers (Phosphorylated-tau [P-tau], Amyloid Beta 1-42 [Abeta 1-42], Total Tau [T-tau]) at Week 104 (Double-Blind Treatment Phase)</title>
        <description>CSF biomarker phospho-tau (p-tau) is an indicator of neuronal injury and neurodegeneration. An elevation in levels of tau, as well as specific p-tau species, is thought to be a marker for progressive cellular degeneration in AD.</description>
        <time_frame>Baseline, Week 104</time_frame>
        <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. The Placebo Match Gantenerumab 225mg (Parts 1 and 2) arm consisted of participants with the ApoE 2e4 mutation who were excluded from the Gantenerumab 225 mg (Parts 1 and 2) arm. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Placebo SC injection (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab 105 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Match Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received matching Placebo to Gantenerumab 225 mg by SC injection q4w for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Cerebrospinal Fluid Biomarkers (Phosphorylated-tau [P-tau], Amyloid Beta 1-42 [Abeta 1-42], Total Tau [T-tau]) at Week 104 (Double-Blind Treatment Phase)</title>
          <description>CSF biomarker phospho-tau (p-tau) is an indicator of neuronal injury and neurodegeneration. An elevation in levels of tau, as well as specific p-tau species, is thought to be a marker for progressive cellular degeneration in AD.</description>
          <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. The Placebo Match Gantenerumab 225mg (Parts 1 and 2) arm consisted of participants with the ApoE 2e4 mutation who were excluded from the Gantenerumab 225 mg (Parts 1 and 2) arm. Data presented below is only for participants included in the actual analysis.</population>
          <units>Percentage Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>p-tau (Week 104)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.77" spread="20.69"/>
                    <measurement group_id="O2" value="-4.78" spread="11.9"/>
                    <measurement group_id="O3" value="-7.34" spread="10.09"/>
                    <measurement group_id="O4" value="2.84" spread="23.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t-tau (Week 104)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" spread="19.95"/>
                    <measurement group_id="O2" value="-1.36" spread="12.89"/>
                    <measurement group_id="O3" value="-2.12" spread="11.01"/>
                    <measurement group_id="O4" value="3.46" spread="22.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abeta (Week 104)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" spread="36.14"/>
                    <measurement group_id="O2" value="2.45" spread="24.57"/>
                    <measurement group_id="O3" value="15.2" spread="45.24"/>
                    <measurement group_id="O4" value="4.3" spread="39.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis of the Abeta 1-42 CSF biomarker between &quot;Placebo (Parts 1 and 2)&quot; and &quot;Gantenerumab 105 mg (Parts 1 and 2)&quot; treatment arms at Week 104.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9734</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis of the Abeta 1-42 CSF biomarker between &quot;Placebo (Parts 1 and 2)&quot; and &quot;Gantenerumab 225 mg (Parts 1 and 2)&quot; treatment arms at Week 104.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0629</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis of the p-tau CSF biomarker between &quot;Placebo (Parts 1 and 2)&quot; and &quot;Gantenerumab 105 mg (Parts 1 and 2)&quot; treatment arms at Week 104.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0084</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis of the p-tau CSF biomarker between &quot;Placebo (Parts 1 and 2)&quot; and &quot;Gantenerumab 225 mg (Parts 1 and 2)&quot; treatment arms at Week 104.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis of the t-tau CSF biomarker between &quot;Placebo (Parts 1 and 2)&quot; and &quot;Gantenerumab 105 mg (Parts 1 and 2)&quot; treatment arms at Week 104.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0903</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis of the t-tau CSF biomarker between &quot;Placebo (Parts 1 and 2)&quot; and &quot;Gantenerumab 225 mg (Parts 1 and 2)&quot; treatment arms at Week 104.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0434</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Hippocampal Volume at Week 104 (Double-Blind Treatment Phase)</title>
        <description>Change from baseline in hippocampal right volume (HRV) and hippocampal left volume (HLV) were analysed at Week 104 using magnetic resonance imaging.</description>
        <time_frame>Baseline, Week 104</time_frame>
        <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. The Placebo Match Gantenerumab 225mg (Parts 1 and 2) arm consisted of participants with the ApoE 2e4 mutation who were excluded from the Gantenerumab 225 mg (Parts 1 and 2) arm. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Placebo SC injection (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab 105 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Match Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received matching Placebo to Gantenerumab 225 mg by SC injection q4w for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Hippocampal Volume at Week 104 (Double-Blind Treatment Phase)</title>
          <description>Change from baseline in hippocampal right volume (HRV) and hippocampal left volume (HLV) were analysed at Week 104 using magnetic resonance imaging.</description>
          <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. The Placebo Match Gantenerumab 225mg (Parts 1 and 2) arm consisted of participants with the ApoE 2e4 mutation who were excluded from the Gantenerumab 225 mg (Parts 1 and 2) arm. Data presented below is only for participants included in the actual analysis.</population>
          <units>Percentage Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HRV (Week 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.61" spread="4.03"/>
                    <measurement group_id="O2" value="-7.52" spread="3.96"/>
                    <measurement group_id="O3" value="-7.34" spread="3.84"/>
                    <measurement group_id="O4" value="-7.7" spread="4.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HLV (Week 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="4.28"/>
                    <measurement group_id="O2" value="-7.76" spread="3.74"/>
                    <measurement group_id="O3" value="-7.27" spread="3.78"/>
                    <measurement group_id="O4" value="-8.12" spread="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Cortical Composite Sustained Uptake Volume Ratio (SUVr) in Different Brain Regions at Week 156 (Double-Blind Treatment Phase)</title>
        <description>The different regions of the brain that were analyzed included cerebellum gray, whole cerebellum, composite white matter, subcortical white matter, pons and composite reference.</description>
        <time_frame>Baseline, Week 156</time_frame>
        <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. The Placebo Match Gantenerumab 225mg (Parts 1 and 2) arm consisted of participants with the ApoE 2e4 mutation who were excluded from the Gantenerumab 225 mg (Parts 1 and 2) arm. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Placebo SC injection (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab 105 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Match Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received matching Placebo to Gantenerumab 225 mg by SC injection q4w for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Cortical Composite Sustained Uptake Volume Ratio (SUVr) in Different Brain Regions at Week 156 (Double-Blind Treatment Phase)</title>
          <description>The different regions of the brain that were analyzed included cerebellum gray, whole cerebellum, composite white matter, subcortical white matter, pons and composite reference.</description>
          <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. The Placebo Match Gantenerumab 225mg (Parts 1 and 2) arm consisted of participants with the ApoE 2e4 mutation who were excluded from the Gantenerumab 225 mg (Parts 1 and 2) arm. Data presented below is only for participants included in the actual analysis.</population>
          <units>Percentage Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cerebellum gray (Week 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.26" spread="9.1"/>
                    <measurement group_id="O2" value="2.7" spread="10.59"/>
                    <measurement group_id="O3" value="-8.36" spread="9.11"/>
                    <measurement group_id="O4" value="5.95" spread="11.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Whole Cerebellum (Week 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.41" spread="7.13"/>
                    <measurement group_id="O2" value="2.07" spread="8.65"/>
                    <measurement group_id="O3" value="-8.44" spread="8.06"/>
                    <measurement group_id="O4" value="5.17" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite White Matter (Week 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" spread="3.18"/>
                    <measurement group_id="O2" value="-0.87" spread="2.95"/>
                    <measurement group_id="O3" value="-4.86" spread="6.35"/>
                    <measurement group_id="O4" value="3.07" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subcortical White Matter (Week 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" spread="4.95"/>
                    <measurement group_id="O2" value="1.69" spread="4.45"/>
                    <measurement group_id="O3" value="-0.42" spread="8.26"/>
                    <measurement group_id="O4" value="4.59" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pons (Week 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="2.51"/>
                    <measurement group_id="O2" value="-2.83" spread="3.39"/>
                    <measurement group_id="O3" value="-6.99" spread="5.65"/>
                    <measurement group_id="O4" value="2.1" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite Reference (Week 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="3.48"/>
                    <measurement group_id="O2" value="1.19" spread="5.63"/>
                    <measurement group_id="O3" value="-6.75" spread="6.1"/>
                    <measurement group_id="O4" value="4.46" spread="4.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gantenerumab Plasma Concentrations at Different Time Points (Double-Blind Treatment Phase)</title>
        <description>The PK analyses includes tabulation of plasma concentration data and summarisation of plasma concentrations by visits with participants grouped according to treatment received. Descriptive summary statistics for the Arithmetic Mean and Standard Deviation are presented below.</description>
        <time_frame>Pre-Dose: Weeks 8, 20, 44, 68 and 100; Post-Dose: Weeks 1, 53 and 101</time_frame>
        <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. Data presented below is only for participants included in the actual analysis and note that participants who received dose reduction were excluded from this PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Gantenerumab 105 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Gantenerumab Plasma Concentrations at Different Time Points (Double-Blind Treatment Phase)</title>
          <description>The PK analyses includes tabulation of plasma concentration data and summarisation of plasma concentrations by visits with participants grouped according to treatment received. Descriptive summary statistics for the Arithmetic Mean and Standard Deviation are presented below.</description>
          <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB. Data presented below is only for participants included in the actual analysis and note that participants who received dose reduction were excluded from this PK analysis.</population>
          <units>Âµg/ml (micrograms per milliliter)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (Post-Dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="239"/>
                    <count group_id="O2" value="227"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" spread="2.36"/>
                    <measurement group_id="O2" value="7.4" spread="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (Pre-Dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="1.84"/>
                    <measurement group_id="O2" value="5.92" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (Pre-Dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="2.15"/>
                    <measurement group_id="O2" value="7.66" spread="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (Pre-Dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                    <count group_id="O2" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.08" spread="2.44"/>
                    <measurement group_id="O2" value="8.22" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 53 (Post-Dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="195"/>
                    <count group_id="O2" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.77" spread="3.94"/>
                    <measurement group_id="O2" value="15" spread="9.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 68 (Pre-Dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="165"/>
                    <count group_id="O2" value="155"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.95" spread="2.35"/>
                    <measurement group_id="O2" value="8.91" spread="4.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 100 (Pre-Dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.35" spread="2.34"/>
                    <measurement group_id="O2" value="9.4" spread="4.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 101 (Post-Dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.32" spread="3.53"/>
                    <measurement group_id="O2" value="16.63" spread="7.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Mini Mental State Exam (MMSE) Score at Week 104 (Double-Blind Treatment Phase)</title>
        <description>The MMSE is a brief, practical screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement.</description>
        <time_frame>Baseline, Week 104</time_frame>
        <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Placebo SC injection (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab 105 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Mini Mental State Exam (MMSE) Score at Week 104 (Double-Blind Treatment Phase)</title>
          <description>The MMSE is a brief, practical screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement.</description>
          <population>The Intent-To-Treat (ITT) population was defined as all participants who had received any dose of study treatment and had at least one post-baseline assessment of CDR-SOB.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.31" spread="3.23"/>
                    <measurement group_id="O2" value="-2.46" spread="3.68"/>
                    <measurement group_id="O3" value="-2.25" spread="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) (Double-Blind Treatment Phase)</title>
        <description>An Adverse Event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
        <time_frame>Baseline up until a maximum of 4.5 years</time_frame>
        <population>The Safety population was defined as all participants who had received at least one dose of study drug, regardless of whether the participant withdrew prematurely or not. All safety data was analyzed according to study drug actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Placebo by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab 105 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) (Double-Blind Treatment Phase)</title>
          <description>An Adverse Event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
          <population>The Safety population was defined as all participants who had received at least one dose of study drug, regardless of whether the participant withdrew prematurely or not. All safety data was analyzed according to study drug actually received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250"/>
                    <measurement group_id="O2" value="241"/>
                    <measurement group_id="O3" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-Drug Antibodies (ADAs) (Double-Blind Treatment Phase)</title>
        <description>Participants were considered positive or negative for ADA based on their baseline and post-baseline sample results. The number and percentage of participants with confirmed positive ADA levels were determined for Gantenerumab and Placebo groups. The prevalence of ADA at baseline was calculated as the proportion of participants with confirmed positive ADA levels at baseline relative to the total number of participants with a sample available at baseline. The incidence of treatment-emergent ADAs was determined as the proportion of participants with confirmed post-baseline positive ADAs relative to the total number of participants that had at least one post-baseline sample available for ADA analysis.</description>
        <time_frame>Baseline up until a maximum of 4.5 years</time_frame>
        <population>The Safety population was defined as all participants who had received at least one dose of study drug, regardless of whether the participant withdrew prematurely or not. All safety data was analyzed according to study drug actually received. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Placebo by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab 105 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Gantenerumab 225 mg (Parts 1 and 2)</title>
            <description>Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-Drug Antibodies (ADAs) (Double-Blind Treatment Phase)</title>
          <description>Participants were considered positive or negative for ADA based on their baseline and post-baseline sample results. The number and percentage of participants with confirmed positive ADA levels were determined for Gantenerumab and Placebo groups. The prevalence of ADA at baseline was calculated as the proportion of participants with confirmed positive ADA levels at baseline relative to the total number of participants with a sample available at baseline. The incidence of treatment-emergent ADAs was determined as the proportion of participants with confirmed post-baseline positive ADAs relative to the total number of participants that had at least one post-baseline sample available for ADA analysis.</description>
          <population>The Safety population was defined as all participants who had received at least one dose of study drug, regardless of whether the participant withdrew prematurely or not. All safety data was analyzed according to study drug actually received. Data presented below is only for participants included in the actual analysis.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="266"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline ADAs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="259"/>
                    <count group_id="O2" value="266"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="7.5"/>
                    <measurement group_id="O3" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Emergent ADAs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="259"/>
                    <count group_id="O2" value="258"/>
                    <count group_id="O3" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="7.0"/>
                    <measurement group_id="O3" value="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog-11) Scores at Week 156 (OLE Phase)</title>
        <description>The ADAS-Cog-11 assesses multiple cognitive domains including memory, comprehension, praxis, orientation, and spontaneous speech. Most of these are assessed by tests although some are rated by the clinician on a 5-point scale. The score range for ADAS-Cog-11 is from 0 to 70 with higher scores representing severe dysfunction.</description>
        <time_frame>Baseline, Week 156</time_frame>
        <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2) Switched to Gantenerumab Up to 1200mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Placebo by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog-11) Scores at Week 156 (OLE Phase)</title>
          <description>The ADAS-Cog-11 assesses multiple cognitive domains including memory, comprehension, praxis, orientation, and spontaneous speech. Most of these are assessed by tests although some are rated by the clinician on a 5-point scale. The score range for ADAS-Cog-11 is from 0 to 70 with higher scores representing severe dysfunction.</description>
          <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="7.3"/>
                    <measurement group_id="O2" value="8.9" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Total Score at Week 156 (OLE Phase)</title>
        <description>The CDR (Clinical Dementia Rating) is obtained through semi-structured interviews of participants and informants, and cognitive functioning is rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment. The CDR-SOB (Clinical Dementia Rating-Sum of Boxes) is based on summing each of the domain box scores with total scores ranging from 0-18, where lower total scores represent better outcomes and higher total scores represent worse outcomes.</description>
        <time_frame>Baseline, Week 156</time_frame>
        <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2) Switched to Gantenerumab Up to 1200mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Placebo by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Total Score at Week 156 (OLE Phase)</title>
          <description>The CDR (Clinical Dementia Rating) is obtained through semi-structured interviews of participants and informants, and cognitive functioning is rated in six domains of functioning: memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment. The CDR-SOB (Clinical Dementia Rating-Sum of Boxes) is based on summing each of the domain box scores with total scores ranging from 0-18, where lower total scores represent better outcomes and higher total scores represent worse outcomes.</description>
          <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="2.4"/>
                    <measurement group_id="O2" value="2.8" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog-13) Scores at Week 156 (OLE Phase)</title>
        <description>The ADAS-Cog-13 assesses multiple cognitive domains including memory, comprehension, praxis, orientation, and spontaneous speech. The score range for ADAS-Cog-13 is from 0 to 85 with higher scores representing severe dysfunction.</description>
        <time_frame>Baseline, Week 156</time_frame>
        <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2) Switched to Gantenerumab Up to 1200mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Placebo by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog-13) Scores at Week 156 (OLE Phase)</title>
          <description>The ADAS-Cog-13 assesses multiple cognitive domains including memory, comprehension, praxis, orientation, and spontaneous speech. The score range for ADAS-Cog-13 is from 0 to 85 with higher scores representing severe dysfunction.</description>
          <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="8.2"/>
                    <measurement group_id="O2" value="10.4" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Dementia at Week 156 (OLE Phase)</title>
        <description>Time to Onset of Dementia was defined as the time interval between the first treatment date and the date that participant is assessed as having Alzheimer-type dementia by investigators.</description>
        <time_frame>Baseline, Week 156</time_frame>
        <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2) Switched to Gantenerumab Up to 1200mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Placebo by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Dementia at Week 156 (OLE Phase)</title>
          <description>Time to Onset of Dementia was defined as the time interval between the first treatment date and the date that participant is assessed as having Alzheimer-type dementia by investigators.</description>
          <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.18" lower_limit="9.90" upper_limit="66.97"/>
                    <measurement group_id="O2" value="50.82" lower_limit="32.04" upper_limit="66.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Free and Cued Selective Reminding Test (FCSRT) Score at Week 156 (OLE Phase)</title>
        <description>FCSRT assesses verbal episodic memory. Performances in free recalls, cued recalls and in a recognition task were analyzed, as the process of encoding is controlled. Participants were asked to remember a list of 16 words. Three tasks of free and cued recalls, as well as 1 recognition task and one delayed recall give the scores. Total recall was obtained by the addition of cued recalls to free recalls. Maximum score is 48 for immediate: 16 words multiplied by (*) 3 corresponding to immediate free recall + immediate cued recall + immediate recognition test. Maximum score is 64 (better score) when delayed recall: 16 words*4. The minimum score is 0 (worse).</description>
        <time_frame>Baseline, Week 156</time_frame>
        <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2) Switched to Gantenerumab Up to 1200mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Placebo by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Free and Cued Selective Reminding Test (FCSRT) Score at Week 156 (OLE Phase)</title>
          <description>FCSRT assesses verbal episodic memory. Performances in free recalls, cued recalls and in a recognition task were analyzed, as the process of encoding is controlled. Participants were asked to remember a list of 16 words. Three tasks of free and cued recalls, as well as 1 recognition task and one delayed recall give the scores. Total recall was obtained by the addition of cued recalls to free recalls. Maximum score is 48 for immediate: 16 words multiplied by (*) 3 corresponding to immediate free recall + immediate cued recall + immediate recognition test. Maximum score is 64 (better score) when delayed recall: 16 words*4. The minimum score is 0 (worse).</description>
          <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="9.3"/>
                    <measurement group_id="O2" value="-4.1" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Functional Activities Questionnaire (FAQ) Score at Week 156 (OLE Phase)</title>
        <description>Participants completed the FAQ for physical function. Overall scores ranged from 0 (independent) to 30 (dependent) where lower scores represented an improvement in physical function.</description>
        <time_frame>Baseline, Week 156</time_frame>
        <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2) Switched to Gantenerumab Up to 1200mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Placebo by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Functional Activities Questionnaire (FAQ) Score at Week 156 (OLE Phase)</title>
          <description>Participants completed the FAQ for physical function. Overall scores ranged from 0 (independent) to 30 (dependent) where lower scores represented an improvement in physical function.</description>
          <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="5.3"/>
                    <measurement group_id="O2" value="6.8" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CDR-Global Score at Week 156 (OLE Phase)</title>
        <description>The CDR-GS represents a semi-structured interview which rates impairment in 6 categories (memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care) on a 5-point scale in which CDR 0 = no dementia and CDR 0.5, 1, 2 or 3 = questionable, mild, moderate or severe dementia respectively. The range in scores for the CDR-GS is from 0 to 3 and a high score on the CDR-GS would indicate a high disease severity.</description>
        <time_frame>Baseline, Week 156</time_frame>
        <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2) Switched to Gantenerumab Up to 1200mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Placebo by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CDR-Global Score at Week 156 (OLE Phase)</title>
          <description>The CDR-GS represents a semi-structured interview which rates impairment in 6 categories (memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care) on a 5-point scale in which CDR 0 = no dementia and CDR 0.5, 1, 2 or 3 = questionable, mild, moderate or severe dementia respectively. The range in scores for the CDR-GS is from 0 to 3 and a high score on the CDR-GS would indicate a high disease severity.</description>
          <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.6"/>
                    <measurement group_id="O2" value="0.5" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Hippocampal Volume at Week 152 (OLE Phase)</title>
        <description>Change from baseline in hippocampal right volume (HRV) and hippocampal left volume (HLV) were analysed at Week 152 using magnetic resonance imaging.</description>
        <time_frame>Baseline, Week 152</time_frame>
        <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2) Switched to Gantenerumab Up to 1200mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Placebo by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Hippocampal Volume at Week 152 (OLE Phase)</title>
          <description>Change from baseline in hippocampal right volume (HRV) and hippocampal left volume (HLV) were analysed at Week 152 using magnetic resonance imaging.</description>
          <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
          <units>Percentage Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HRV (Week 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="8.4"/>
                    <measurement group_id="O2" value="16.1" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HLV (Week 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="13.0"/>
                    <measurement group_id="O2" value="18.0" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Cortical Composite Sustained Uptake Volume Ratio (SUVr) in Different Brain Regions at Week 156 (OLE Phase)</title>
        <description>The regions of the brain that were analyzed included cerebellum gray and composite reference.</description>
        <time_frame>Baseline, Week 156</time_frame>
        <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Cortical Composite Sustained Uptake Volume Ratio (SUVr) in Different Brain Regions at Week 156 (OLE Phase)</title>
          <description>The regions of the brain that were analyzed included cerebellum gray and composite reference.</description>
          <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
          <units>Percentage Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cerebellum gray (Week 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite Reference (Week 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.4" spread="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gantenerumab Plasma Concentrations at Different Time Points (OLE Phase)</title>
        <description>The PK analyses includes tabulation of plasma concentration data and summarisation of plasma concentrations by visits with participants grouped according to treatment received. Descriptive summary statistics for the Arithmetic Mean and Standard Deviation are presented below.</description>
        <time_frame>Pre-Dose: Weeks 64, 100, 104, 136, 156 and 208; Post-Dose: Week 101</time_frame>
        <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis and note that participants who received dose reduction were excluded from this PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Gantenerumab 1200 mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at a dose of 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Gantenerumab Plasma Concentrations at Different Time Points (OLE Phase)</title>
          <description>The PK analyses includes tabulation of plasma concentration data and summarisation of plasma concentrations by visits with participants grouped according to treatment received. Descriptive summary statistics for the Arithmetic Mean and Standard Deviation are presented below.</description>
          <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis and note that participants who received dose reduction were excluded from this PK analysis.</population>
          <units>Âµg/ml (micrograms per milliliter)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 64 (Pre-Dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" spread="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 100 (Pre-Dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 101 (Post-Dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.5" spread="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 (Pre-Dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 136 (Pre-Dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 (Pre-Dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6" spread="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208 (Pre-Dose)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" spread="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Mini Mental State Exam (MMSE) Score at Week 156 (OLE Phase)</title>
        <description>The MMSE is a brief, practical screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement.</description>
        <time_frame>Baseline, Week 156</time_frame>
        <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2) Switched to Gantenerumab Up to 1200mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Placebo by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Mini Mental State Exam (MMSE) Score at Week 156 (OLE Phase)</title>
          <description>The MMSE is a brief, practical screening test for cognitive dysfunction. The test consists of five sections (orientation, registration, attention-calculation, recall, and language); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement.</description>
          <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="4.3"/>
                    <measurement group_id="O2" value="-4.7" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Anti-Drug Antibodies (ADAs) (OLE Phase)</title>
        <description>Participants were considered positive or negative for ADA based on their baseline and post-baseline sample results. The number and percentage of participants with confirmed positive ADA levels were determined. The prevalence of ADA at baseline was calculated as the proportion of participants with confirmed positive ADA levels at baseline relative to the total number of participants with a sample available at baseline. The incidence of treatment-emergent ADAs was determined as the proportion of participants with confirmed post-baseline positive ADAs relative to the total number of participants that had at least one post-baseline sample available for ADA analysis.</description>
        <time_frame>Baseline up until a maximum of 5 years</time_frame>
        <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Parts 1 and 2) Switched to Gantenerumab Up to 1200mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Placebo by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
          <group group_id="O2">
            <title>Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])</title>
            <description>Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Anti-Drug Antibodies (ADAs) (OLE Phase)</title>
          <description>Participants were considered positive or negative for ADA based on their baseline and post-baseline sample results. The number and percentage of participants with confirmed positive ADA levels were determined. The prevalence of ADA at baseline was calculated as the proportion of participants with confirmed positive ADA levels at baseline relative to the total number of participants with a sample available at baseline. The incidence of treatment-emergent ADAs was determined as the proportion of participants with confirmed post-baseline positive ADAs relative to the total number of participants that had at least one post-baseline sample available for ADA analysis.</description>
          <population>The Safety population was defined as all participants who had received at least one dose of Gantenerumab during the OLE phase. All participants in the Safety population also had at least one post-OLE baseline MRI. Data presented below is only for participants included in the actual analysis.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline ADAs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Emergent ADAs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up until a maximum of 9.5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Parts 1 and 2)</title>
          <description>Participants with Alzheimer's disease received Placebo by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
        </group>
        <group group_id="E2">
          <title>Gantenerumab 105 mg (Parts 1 and 2)</title>
          <description>Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
        </group>
        <group group_id="E3">
          <title>Gantenerumab 225 mg (Parts 1 and 2)</title>
          <description>Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.</description>
        </group>
        <group group_id="E4">
          <title>Placebo (Parts 1 and 2) Switched to Gantenerumab Up to 1200mg (Part 3 Open-Label Extension [OLE])</title>
          <description>Participants with Alzheimer's disease who had received Placebo by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
        </group>
        <group group_id="E5">
          <title>Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])</title>
          <description>Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="271"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="260"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Myocardial rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes insipidus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Type I hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pleural infection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Radiation mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Urinary retention postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Biliary cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Small cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Benign ovarian tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Bone sarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Breast cancer stage II</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Glioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pharyngeal neoplasm benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Renal oncocytoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ARIA-E</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Dementia with Lewy bodies</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Retrograde amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Radial nerve palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Neuropsychiatric symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Suicidal behaviour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Behavioral and psychological symptoms of dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Rotator cuff repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Urethral caruncle removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Spinal decompression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Urethral dilation procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="188" subjects_at_risk="271"/>
                <counts group_id="E3" subjects_affected="189" subjects_at_risk="260"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="49"/>
                <counts group_id="E5" subjects_affected="87" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="266"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="271"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="260"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E5" events="14" subjects_affected="11" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E5" events="9" subjects_affected="6" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E2" events="133" subjects_affected="29" subjects_at_risk="271"/>
                <counts group_id="E3" events="114" subjects_affected="35" subjects_at_risk="260"/>
                <counts group_id="E4" events="196" subjects_affected="17" subjects_at_risk="49"/>
                <counts group_id="E5" events="359" subjects_affected="36" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="266"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="271"/>
                <counts group_id="E3" events="20" subjects_affected="15" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="266"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="271"/>
                <counts group_id="E3" events="18" subjects_affected="14" subjects_at_risk="260"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E5" events="9" subjects_affected="7" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="266"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="271"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="260"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="34" subjects_affected="17" subjects_at_risk="266"/>
                <counts group_id="E2" events="40" subjects_affected="30" subjects_at_risk="271"/>
                <counts group_id="E3" events="35" subjects_affected="20" subjects_at_risk="260"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E5" events="23" subjects_affected="15" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="266"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="271"/>
                <counts group_id="E3" events="21" subjects_affected="18" subjects_at_risk="260"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E5" events="19" subjects_affected="10" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="37" subjects_affected="25" subjects_at_risk="266"/>
                <counts group_id="E2" events="25" subjects_affected="16" subjects_at_risk="271"/>
                <counts group_id="E3" events="38" subjects_affected="22" subjects_at_risk="260"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E5" events="25" subjects_affected="15" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="42" subjects_affected="28" subjects_at_risk="266"/>
                <counts group_id="E2" events="32" subjects_affected="23" subjects_at_risk="271"/>
                <counts group_id="E3" events="38" subjects_affected="27" subjects_at_risk="260"/>
                <counts group_id="E4" events="20" subjects_affected="13" subjects_at_risk="49"/>
                <counts group_id="E5" events="29" subjects_affected="17" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="21" subjects_at_risk="266"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="271"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="260"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="33" subjects_affected="26" subjects_at_risk="266"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="271"/>
                <counts group_id="E3" events="32" subjects_affected="26" subjects_at_risk="260"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="266"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="271"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits</sub_title>
                <counts group_id="E1" events="51" subjects_affected="31" subjects_at_risk="266"/>
                <counts group_id="E2" events="92" subjects_affected="58" subjects_at_risk="271"/>
                <counts group_id="E3" events="64" subjects_affected="36" subjects_at_risk="260"/>
                <counts group_id="E4" events="12" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E5" events="44" subjects_affected="17" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Amyloid related imaging abnormality-oedema/effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="271"/>
                <counts group_id="E3" events="36" subjects_affected="34" subjects_at_risk="260"/>
                <counts group_id="E4" events="21" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E5" events="45" subjects_affected="29" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="266"/>
                <counts group_id="E2" events="27" subjects_affected="21" subjects_at_risk="271"/>
                <counts group_id="E3" events="35" subjects_affected="26" subjects_at_risk="260"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E5" events="18" subjects_affected="14" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="50" subjects_affected="36" subjects_at_risk="266"/>
                <counts group_id="E2" events="47" subjects_affected="34" subjects_at_risk="271"/>
                <counts group_id="E3" events="36" subjects_affected="25" subjects_at_risk="260"/>
                <counts group_id="E4" events="11" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E5" events="18" subjects_affected="12" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E5" events="10" subjects_affected="8" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="266"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="271"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="260"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E5" events="9" subjects_affected="6" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="266"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="271"/>
                <counts group_id="E3" events="25" subjects_affected="25" subjects_at_risk="260"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="266"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="271"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="260"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E5" events="12" subjects_affected="8" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="266"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="271"/>
                <counts group_id="E3" events="23" subjects_affected="20" subjects_at_risk="260"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E5" events="11" subjects_affected="8" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800 821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

